The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
[molybdate co-treated with INS1 protein] results in increased phosphorylation of INSR protein; [molybdate co-treated with INS1 protein] results in increased phosphorylation of IRS4 protein; [molybdate co-treated with Vanadates co-treated with INS1 protein] results in increased phosphorylation of INSR protein; molybdate promotes the reaction [[Vanadates co-treated with INS1 protein] results in increased phosphorylation of IRS4 protein]; Vanadates promotes the reaction [[molybdate co-treated with INS1 protein] results in increased phosphorylation of IRS4 protein]
[molybdate co-treated with INS1 protein] results in increased phosphorylation of INSR protein; [molybdate co-treated with Vanadates co-treated with INS1 protein] results in increased phosphorylation of INSR protein
[molybdate co-treated with INS1 protein] results in increased phosphorylation of IRS4 protein; molybdate promotes the reaction [[Vanadates co-treated with INS1 protein] results in increased phosphorylation of IRS4 protein]; Vanadates promotes the reaction [[molybdate co-treated with INS1 protein] results in increased phosphorylation of IRS4 protein]
molybdenum trioxide results in decreased activity of CAT protein chromous chloride affects the reaction [molybdenum trioxide results in decreased activity of CAT protein]; molybdenum trioxide affects the reaction [chromous chloride results in decreased activity of CAT protein]
sodium molybdate(VI) promotes the reaction [Tetrachlorodibenzodioxin binds to AHR protein] sodium molybdate(VI) inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein] sodium molybdate(VI) results in increased activity of AHR protein
[tetrathiomolybdate binds to APP 5' UTR] which results in decreased expression of APP protein; [tetrathiomolybdate binds to APP 5' UTR] which results in decreased secretion of APP protein modified form
[Copper deficiency co-treated with tetrathiomolybdate] results in increased cleavage of BCL2L11 protein; [Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of BCL2L11 protein
[Copper deficiency co-treated with tetrathiomolybdate] results in increased cleavage of CASP3 protein; [Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of CASP3 protein
[Copper deficiency co-treated with tetrathiomolybdate] results in increased cleavage of CASP8 protein; [Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of CASP8 protein
tetrathiomolybdate inhibits the reaction [Bleomycin results in increased expression of CCL2 mRNA]; tetrathiomolybdate inhibits the reaction [Bleomycin results in increased expression of CCL2 protein]; tetrathiomolybdate inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL2 mRNA]; tetrathiomolybdate inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of and results in increased expression of CCL2 protein] tetrathiomolybdate inhibits the reaction [Copper Sulfate results in increased expression of CCL2 mRNA]; tetrathiomolybdate inhibits the reaction [Copper Sulfate results in increased expression of CCL2 protein]
tetrathiomolybdate results in decreased activity of CP protein tetrathiomolybdate results in decreased expression of CP protein tetrathiomolybdate results in decreased secretion of CP protein tetrathiomolybdate inhibits the reaction [Bleomycin results in increased expression of CP protein]
[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; tetrathiomolybdate inhibits the reaction [EGF protein results in increased oxidation of PTPN1 protein]; tetrathiomolybdate inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]
[Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of ELN mRNA; [Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of ELN protein
[Copper deficiency co-treated with tetrathiomolybdate] inhibits the reaction [EP300 protein binds to HIF1A protein]; [Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of EP300 protein
[Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of FBLN1 mRNA; [Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of FBLN1 protein
[Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of FBLN5 mRNA; [Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of FBLN5 protein
[Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of FBN1 mRNA; [Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of FBN1 protein
[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]; Vanadates inhibits the reaction [[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]]; Vanadates inhibits the reaction [[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]]; Vanadates inhibits the reaction [tetrathiomolybdate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]]; Vanadates inhibits the reaction [tetrathiomolybdate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]]
[Copper deficiency co-treated with tetrathiomolybdate] inhibits the reaction [EP300 protein binds to HIF1A protein]; [Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of HIF1A protein
tetrathiomolybdate results in decreased expression of HMOX1 protein tetrathiomolybdate analog results in increased expression of HMOX1 mRNA; tetrathiomolybdate analog results in increased expression of HMOX1 protein [tetrathiomolybdate analog results in increased abundance of Superoxides] which results in increased reduction of HMOX1 protein; Acetylcysteine inhibits the reaction [tetrathiomolybdate analog results in increased expression of HMOX1 protein]; Copper inhibits the reaction [tetrathiomolybdate analog results in increased expression of HMOX1 protein]
tetrathiomolybdate inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of ICAM1 mRNA]; tetrathiomolybdate inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of and results in increased expression of ICAM1 protein] tetrathiomolybdate inhibits the reaction [Copper Sulfate results in increased expression of ICAM1 mRNA]; tetrathiomolybdate inhibits the reaction [Copper Sulfate results in increased expression of ICAM1 protein]
[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [IGF1 protein results in increased phosphorylation of MAPK1 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [IGF1 protein results in increased phosphorylation of MAPK3 protein]; tetrathiomolybdate inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein]
tetrathiomolybdate analog results in decreased expression of IL2RA mRNA tetrathiomolybdate inhibits the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein]]
[Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of LOX mRNA; [Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of LOX protein
[Copper deficiency co-treated with tetrathiomolybdate] results in decreased phosphorylation of MAPK1 protein tetrathiomolybdate results in decreased phosphorylation of MAPK1 protein [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [IGF1 protein results in increased phosphorylation of MAPK1 protein]; Hydrogen Peroxide inhibits the reaction [tetrathiomolybdate results in decreased phosphorylation of MAPK1 protein]; Vanadates inhibits the reaction [[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]]; Vanadates inhibits the reaction [tetrathiomolybdate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]] tetrathiomolybdate analog results in increased phosphorylation of MAPK1 protein
[Copper deficiency co-treated with tetrathiomolybdate] results in decreased phosphorylation of MAPK3 protein tetrathiomolybdate results in decreased phosphorylation of MAPK3 protein tetrathiomolybdate analog results in increased phosphorylation of MAPK3 protein [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [IGF1 protein results in increased phosphorylation of MAPK3 protein]; Hydrogen Peroxide inhibits the reaction [tetrathiomolybdate results in decreased phosphorylation of MAPK3 protein]; Vanadates inhibits the reaction [[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]]; Vanadates inhibits the reaction [tetrathiomolybdate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]]
[tetrathiomolybdate results in increased expression of SLC31A1 mRNA] which results in decreased susceptibility to oxaliplatin; [tetrathiomolybdate results in increased expression of SLC31A1 mRNA] which results in increased susceptibility to Carboplatin; [tetrathiomolybdate results in increased expression of SLC31A1 mRNA] which results in increased susceptibility to Cisplatin; tetrathiomolybdate promotes the reaction [SP1 protein binds to SLC31A1 promoter]
tetrathiomolybdate results in decreased expression of SOD1 protein tetrathiomolybdate analog affects the localization of SOD1 protein tetrathiomolybdate results in decreased activity of SOD1 protein [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [IGF1 protein results in increased phosphorylation of MAPK1 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [IGF1 protein results in increased phosphorylation of MAPK3 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] which results in decreased abundance of Hydrogen Peroxide; [tetrathiomolybdate results in decreased activity of SOD1 protein] which results in increased abundance of Superoxides; Vanadates inhibits the reaction [[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]]; Vanadates inhibits the reaction [[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]] tetrathiomolybdate analog results in decreased expression of SOD1 mRNA
[tetrathiomolybdate results in decreased abundance of Copper] which results in increased expression of SP1 protein; tetrathiomolybdate promotes the reaction [SP1 protein binds to SLC31A1 promoter]; tetrathiomolybdate promotes the reaction [SP1 protein binds to SP1 promoter] tetrathiomolybdate results in increased expression of SP1; tetrathiomolybdate results in increased expression of SP1 mRNA tetrathiomolybdate results in increased activity of SP1 protein
tetrathiomolybdate inhibits the reaction [Bleomycin results in increased expression of TNF mRNA]; tetrathiomolybdate inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; tetrathiomolybdate inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF mRNA]; tetrathiomolybdate inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of TNF protein]
tetrathiomolybdate inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of VCAM1 mRNA]; tetrathiomolybdate inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of and results in increased expression of VCAM1 protein] tetrathiomolybdate inhibits the reaction [Copper Sulfate results in increased expression of VCAM1 mRNA]; tetrathiomolybdate inhibits the reaction [Copper Sulfate results in increased expression of VCAM1 protein]
[Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of VEGFA mRNA; [Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of VEGFA protein tetrathiomolybdate results in decreased expression of VEGFA protein